{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T16:14:39Z","timestamp":1790957679547,"version":"4.1.0"},"reference-count":150,"publisher":"Spandidos Publications","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J Mol Med"],"DOI":"10.3892\/ijmm.2022.5206","type":"journal-article","created":{"date-parts":[[2022,11,18]],"date-time":"2022-11-18T11:18:01Z","timestamp":1668770281000},"source":"Crossref","is-referenced-by-count":19,"title":["Exosomal delivery of TRAIL and miR\u2011335 for the\u00a0treatment of hepatocellular carcinoma (Review)"],"prefix":"10.3892","volume":"51","author":[{"given":"Nikita","family":"Thapa","sequence":"first","affiliation":[{"name":"CK\u2011Exogene, Inc., Seongnam, Gyeonggi\u2011do 13201, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Chwae","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Ajou University School of Medicine, Suwon, Gyeonggi\u2011do 16499, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwang","family":"Yoo","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Chung\u2011Ang University College of Medicine, Seoul 06973, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tae-Bin","family":"Won","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology, Seoul National University Hospital, Seoul 03080, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daewook","family":"Kang","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Ajou University School of Medicine, Suwon, Gyeonggi\u2011do 16499, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daae","family":"Choi","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Ajou University School of Medicine, Suwon, Gyeonggi\u2011do 16499, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaeyoung","family":"Kim","sequence":"additional","affiliation":[{"name":"CK\u2011Exogene, Inc., Seongnam, Gyeonggi\u2011do 13201, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2022,11,18]]},"reference":[{"key":"key20221222114858_b1-ijmm-51-1-05206","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"key20221222114858_b2-ijmm-51-1-05206","doi-asserted-by":"publisher","first-page":"2140","DOI":"10.1016\/j.cgh.2015.08.014","article-title":"Hepatocellular carcinoma from epidemiology to prevention: Translating knowledge into practice","volume":"13","author":"Singal","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"key20221222114858_b3-ijmm-51-1-05206","doi-asserted-by":"publisher","first-page":"171","DOI":"10.3389\/fonc.2020.00171","article-title":"Global trends in incidence rates of primary adult liver cancers: A systematic review and meta-analysis","volume":"10","author":"Dasgupta","year":"2020","journal-title":"Front Oncol"},{"key":"key20221222114858_b4-ijmm-51-1-05206","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/j.ramb.2013.03.005","article-title":"Hepatocellular carcinoma: Epidemiology, biology, diagnosis, and therapies","volume":"59","author":"Gomes","year":"2013","journal-title":"Rev Assoc Med Bras (1992)"},{"key":"key20221222114858_b5-ijmm-51-1-05206","doi-asserted-by":"publisher","first-page":"2362","DOI":"10.1158\/1055-9965.EPI-11-0643","article-title":"International trends in liver cancer incidence rates","volume":"20","author":"Center","year":"2011","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"key20221222114858_b6-ijmm-51-1-05206","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/1471-2407-9-33","article-title":"Early and very early hepatocellular carcinoma: When and how much do staging and choice of treatment really matter? A multi-center study","volume":"9","author":"Farinati","year":"2009","journal-title":"BMC Cancer"},{"key":"key20221222114858_b7-ijmm-51-1-05206","doi-asserted-by":"publisher","first-page":"30","DOI":"10.3390\/data2030030","article-title":"Estimating cost savings from early cancer diagnosis","volume":"2","author":"Kakushadze","year":"2017","journal-title":"Data"},{"issue":"Suppl 1","key":"key20221222114858_b8-ijmm-51-1-05206","doi-asserted-by":"publisher","first-page":"S11","DOI":"10.1055\/s-0033-1333632","article-title":"Emerging targeted strategies in advanced hepatocellular carcinoma","volume":"33","author":"Finn","year":"2013","journal-title":"Semin Liver Dis"},{"key":"key20221222114858_b9-ijmm-51-1-05206","volume-title":"World Cancer Report 2014","author":"WHO's International Agency for Research on Cancer (IARC)","year":"2014"},{"key":"key20221222114858_b10-ijmm-51-1-05206","doi-asserted-by":"publisher","first-page":"5282","DOI":"10.3748\/wjg.v23.i29.5282","article-title":"From diagnosis to treatment of hepatocellular carcinoma: An epidemic problem for both developed and developing world","volume":"23","author":"Dimitroulis","year":"2017","journal-title":"World J Gastroenterol"},{"key":"key20221222114858_b11-ijmm-51-1-05206","doi-asserted-by":"publisher","first-page":"3279","DOI":"10.3390\/cancers3033279","article-title":"Assessment of the evolution of cancer treatment therapies","volume":"3","author":"Arruebo","year":"2011","journal-title":"Cancers (Basel)"},{"key":"key20221222114858_b12-ijmm-51-1-05206","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1053\/j.gastro.2008.02.090","article-title":"Diagnosis and treatment of hepatocellular carcinoma","volume":"134","author":"El-Serag","year":"2008","journal-title":"Gastroenterology"},{"key":"key20221222114858_b13-ijmm-51-1-05206","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N Engl J Med"},{"key":"key20221222114858_b14-ijmm-51-1-05206","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1634\/theoncologist.2008-0185","article-title":"Sorafenib for the treatment of unresectable hepatocellular carcinoma","volume":"14","author":"Kane","year":"2009","journal-title":"Oncologist"},{"key":"key20221222114858_b15-ijmm-51-1-05206","doi-asserted-by":"publisher","first-page":"11851","DOI":"10.1158\/0008-5472.CAN-06-1377","article-title":"Sorafenib blocks the RAF\/MEK\/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC\/PRF\/5","volume":"66","author":"Liu","year":"2006","journal-title":"Cancer Res"},{"key":"key20221222114858_b16-ijmm-51-1-05206","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: A randomised phase 3 non-inferiority trial","volume":"391","author":"Kudo","year":"2018","journal-title":"Lancet"},{"key":"key20221222114858_b17-ijmm-51-1-05206","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N Engl J Med"},{"key":"key20221222114858_b18-ijmm-51-1-05206","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1007\/s00535-016-1263-4","article-title":"Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma","volume":"52","author":"Ikeda","year":"2017","journal-title":"J Gastroenterol"},{"key":"key20221222114858_b19-ijmm-51-1-05206","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1038\/nrc1997","article-title":"MicroRNA signatures in human cancers","volume":"6","author":"Calin","year":"2006","journal-title":"Nat Rev Cancer"},{"key":"key20221222114858_b20-ijmm-51-1-05206","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1053\/j.gastro.2007.05.022","article-title":"MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer","volume":"133","author":"Meng","year":"2007","journal-title":"Gastroenterology"},{"key":"key20221222114858_b21-ijmm-51-1-05206","doi-asserted-by":"publisher","DOI":"10.1002\/jcb.28388","article-title":"miR-145-5p inhibits tumor occurrence and metastasis through the NF-\u03baB signaling pathway by targeting TLR4 in malignant melanoma","author":"Jin","year":"2019","journal-title":"J Cell Biochem"},{"key":"key20221222114858_b22-ijmm-51-1-05206","doi-asserted-by":"publisher","first-page":"8474","DOI":"10.18632\/oncotarget.3523","article-title":"MicroRNAs in apoptosis, autophagy and necroptosis","volume":"6","author":"Su","year":"2015","journal-title":"Oncotarget"},{"key":"key20221222114858_b23-ijmm-51-1-05206","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/j.ccell.2017.03.004","article-title":"Cell-cycle-targeting MicroRNAs as therapeutic tools against refractory cancers","volume":"31","author":"Hydbring","year":"2017","journal-title":"Cancer Cell"},{"key":"key20221222114858_b24-ijmm-51-1-05206","doi-asserted-by":"publisher","first-page":"9227","DOI":"10.1038\/s41598-018-27521-y","article-title":"Validation of miRNA prognostic power in hepatocellular carcinoma using expression data of independent datasets","volume":"8","author":"Nagy","year":"2018","journal-title":"Sci Rep"},{"key":"key20221222114858_b25-ijmm-51-1-05206","first-page":"1120","article-title":"Serum miR-1301-3p, miR-335-5p, miR-28-5p and their target B7-H3 may serve as novel biomarkers for colorectal cancer","volume":"24","author":"Wang","year":"2019","journal-title":"J BUON"},{"key":"key20221222114858_b26-ijmm-51-1-05206","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1186\/s12931-019-1184-x","article-title":"miR-335-5p inhibits TGF-\u03b21-induced epithelial-mesenchymal transition in non-small cell lung cancer via ROCK1","volume":"20","author":"Du","year":"2019","journal-title":"Respir Res"},{"key":"key20221222114858_b27-ijmm-51-1-05206","doi-asserted-by":"publisher","first-page":"3557","DOI":"10.7150\/jca.26350","article-title":"The role of MicroRNAs in hepatocellular carcinoma","volume":"9","author":"Xu","year":"2018","journal-title":"J Cancer"},{"key":"key20221222114858_b28-ijmm-51-1-05206","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1186\/s12885-017-3816-1","article-title":"MicroRNA profile in HBV-induced infection and hepatocellular carcinoma","volume":"17","author":"Wang","year":"2017","journal-title":"BMC Cancer"},{"key":"key20221222114858_b29-ijmm-51-1-05206","doi-asserted-by":"publisher","first-page":"785","DOI":"10.4254\/wjh.v10.i11.785","article-title":"Exosomal microRNAs as a potential therapeutic strategy in hepatocellular carcinoma","volume":"10","author":"Gougelet","year":"2018","journal-title":"World J Hepatol"},{"key":"key20221222114858_b30-ijmm-51-1-05206","doi-asserted-by":"publisher","first-page":"3335","DOI":"10.2147\/OTT.S305098","article-title":"Functions and targets of miR-335 in cancer","volume":"14","author":"Ye","year":"2021","journal-title":"Onco Targets Ther"},{"key":"key20221222114858_b31-ijmm-51-1-05206","doi-asserted-by":"publisher","first-page":"6925","DOI":"10.1158\/0008-5472.CAN-10-0141","article-title":"miR-335 directly targets Rb1 (pRb\/p105) in a proximal connection to p53-dependent stress response","volume":"70","author":"Scarola","year":"2010","journal-title":"Cancer Res"},{"key":"key20221222114858_b32-ijmm-51-1-05206","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1111\/cas.13452","article-title":"miR-335 inhibited cell proliferation of lung cancer cells by target Tra2\u03b2","volume":"109","author":"Liu","year":"2018","journal-title":"Cancer Sci"},{"key":"key20221222114858_b33-ijmm-51-1-05206","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s13046-018-0811-6","article-title":"CPNE1 is a target of miR-335-5p and plays an important role in the pathogenesis of non-small cell lung cancer","volume":"37","author":"Tang","year":"2018","journal-title":"J Exp Clin Cancer Res"},{"key":"key20221222114858_b34-ijmm-51-1-05206","first-page":"1725","article-title":"Circ_0009910 promotes proliferation and metastasis of hepatocellular carcinoma cells through miR-335-5p\/ROCK1 axis","volume":"24","author":"Li","year":"2020","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"key20221222114858_b35-ijmm-51-1-05206","doi-asserted-by":"publisher","first-page":"6313","DOI":"10.1007\/s13277-015-3317-2","article-title":"MiR-335 acts as a potential tumor suppressor miRNA via downregulating ROCK1 expression in hepatocellular carcinoma","volume":"36","author":"Liu","year":"2015","journal-title":"Tumour Biol"},{"key":"key20221222114858_b36-ijmm-51-1-05206","doi-asserted-by":"publisher","first-page":"14431","DOI":"10.1002\/jcb.28701","article-title":"LINC00339 regulates ROCK1 by miR-152 to promote cell proliferation and migration in hepatocellular carcinoma","volume":"120","author":"Chen","year":"2019","journal-title":"J Cell Biochem"},{"key":"key20221222114858_b37-ijmm-51-1-05206","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1016\/j.yexcr.2011.05.001","article-title":"Loss of expression of miR-335 is implicated in hepatic stellate cell migration and activation","volume":"317","author":"Chen","year":"2011","journal-title":"Exp Cell Res"},{"key":"key20221222114858_b38-ijmm-51-1-05206","doi-asserted-by":"publisher","first-page":"21937","DOI":"10.1002\/jcp.28757","article-title":"Circ_0005075 promotes hepatocellular carcinoma progression by suppression of microRNA-335","volume":"234","author":"Yang","year":"2019","journal-title":"J Cell Physiol"},{"key":"key20221222114858_b39-ijmm-51-1-05206","first-page":"153","article-title":"Mitogen-activated protein (MAP) kinase pathways: Regulation and physiological functions","volume":"22","author":"Pearson","year":"2001","journal-title":"Endocr Rev"},{"key":"key20221222114858_b40-ijmm-51-1-05206","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.canlet.2014.03.006","article-title":"GABAergic signaling facilitates breast cancer metastasis by promoting ERK1\/2-dependent phosphorylation","volume":"348","author":"Zhang","year":"2014","journal-title":"Cancer Lett"},{"key":"key20221222114858_b41-ijmm-51-1-05206","first-page":"1853","article-title":"MiR-335-5p inhibits proliferation of Huh-7 liver cancer cells via targeting the Oct4\/Akt pathway","volume":"25","author":"Ji","year":"2021","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"key20221222114858_b42-ijmm-51-1-05206","first-page":"6213","article-title":"Up-regulation of miR-335 predicts a favorable prognosis in esophageal squamous cell carcinoma","volume":"7","author":"Zhang","year":"2014","journal-title":"Int J Clin Exp Pathol"},{"key":"key20221222114858_b43-ijmm-51-1-05206","doi-asserted-by":"publisher","first-page":"562","DOI":"10.14348\/molcells.2015.0051","article-title":"miR-335 targets SIAH2 and confers sensitivity to anti-cancer drugs by increasing the expression of HDAC3","volume":"38","author":"Kim","year":"2015","journal-title":"Mol Cells"},{"key":"key20221222114858_b44-ijmm-51-1-05206","doi-asserted-by":"publisher","first-page":"278","DOI":"10.3389\/fonc.2020.00278","article-title":"miR-335 acts as a tumor suppressor and enhances ionizing radiation-induced tumor regression by targeting ROCK1","volume":"10","author":"Cheng","year":"2020","journal-title":"Front Oncol"},{"key":"key20221222114858_b45-ijmm-51-1-05206","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1159\/000430352","article-title":"Serum miR-335 level is associated with the treatment response to trans-arterial chemoembolization and prognosis in patients with hepatocellular carcinoma","volume":"37","author":"Cui","year":"2015","journal-title":"Cell Physiol Biochem"},{"key":"key20221222114858_b46-ijmm-51-1-05206","article-title":"Long noncoding RNA NEAT1 suppresses sorafenib sensitivity of hepatocellular carcinoma cells via regulating miR-335-c-Met","author":"Chen","year":"2019","journal-title":"J Cell Physiol"},{"key":"key20221222114858_b47-ijmm-51-1-05206","doi-asserted-by":"publisher","first-page":"411","DOI":"10.3892\/ijo.2012.1724","article-title":"Epigenetic silencing of miR-335 and its host gene MEST in hepatocellular carcinoma","volume":"42","author":"Dohi","year":"2013","journal-title":"Int J Oncol"},{"key":"key20221222114858_b48-ijmm-51-1-05206","doi-asserted-by":"publisher","first-page":"e3811","DOI":"10.1097\/MD.0000000000003811","article-title":"Comprehensive circular RNA profiling reveals that hsa_ circ_0005075, a new circular RNA biomarker, is involved in hepatocellular crcinoma development","volume":"95","author":"Shang","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"key20221222114858_b49-ijmm-51-1-05206","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1186\/s12885-022-09323-8","article-title":"Circ_0064288 acts as an oncogene of hepatocellular carcinoma cells by inhibiting miR-335-5p expression and promoting ROCK1 expression","volume":"22","author":"Nie","year":"2022","journal-title":"BMC Cancer"},{"key":"key20221222114858_b50-ijmm-51-1-05206","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/S0955-0674(99)80034-9","article-title":"Apoptosis control by death and decoy receptors","volume":"11","author":"Ashkenazi","year":"1999","journal-title":"Curr Opin Cell Biol"},{"key":"key20221222114858_b51-ijmm-51-1-05206","doi-asserted-by":"publisher","first-page":"954","DOI":"10.3390\/cancers11070954","article-title":"Molecular mode of action of TRAIL receptor agonists-common principles and their translational exploitation","volume":"11","author":"Wajant","year":"2019","journal-title":"Cancers (Basel)"},{"key":"key20221222114858_b52-ijmm-51-1-05206","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.pharmthera.2015.09.001","article-title":"Therapeutic applications of TRAIL receptor agonists in cancer and beyond","volume":"155","author":"Amarante-Mendes","year":"2015","journal-title":"Pharmacol Ther"},{"key":"key20221222114858_b53-ijmm-51-1-05206","doi-asserted-by":"publisher","first-page":"e0214847","DOI":"10.1371\/journal.pone.0214847","article-title":"Impact of p53 status on TRAIL-mediated apoptotic and non-apoptotic signaling in cancer cells","volume":"14","author":"Willms","year":"2019","journal-title":"PLoS One"},{"key":"key20221222114858_b54-ijmm-51-1-05206","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1111\/bph.12238","article-title":"Death receptors as targets in cancer","volume":"169","author":"Micheau","year":"2013","journal-title":"Br J Pharmacol"},{"key":"key20221222114858_b55-ijmm-51-1-05206","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1517\/14728222.2015.1049838","article-title":"Targeting TRAIL in the treatment of cancer: New developments","volume":"19","author":"Lim","year":"2015","journal-title":"Expert Opin Ther Targets"},{"key":"key20221222114858_b56-ijmm-51-1-05206","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.ccr.2014.04.028","article-title":"Apo2L\/TRAIL and the death receptor 5 agonist antibody AMG 655 cooperate to promote receptor clustering and antitumor activity","volume":"26","author":"Graves","year":"2014","journal-title":"Cancer Cell"},{"key":"key20221222114858_b57-ijmm-51-1-05206","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/5517","article-title":"Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo","volume":"5","author":"Walczak","year":"1999","journal-title":"Nat Med"},{"key":"key20221222114858_b58-ijmm-51-1-05206","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1084\/jem.188.12.2375","article-title":"Natural killer (NK) cell-mediated cytotoxicity: Differential use of TRAIL and Fas ligand by immature and mature primary human NK cells","volume":"188","author":"Zamai","year":"1998","journal-title":"J Exp Med"},{"key":"key20221222114858_b59-ijmm-51-1-05206","doi-asserted-by":"publisher","first-page":"153","DOI":"10.3892\/ijo.2016.3525","article-title":"Overcoming resistance to TRAIL-induced apoptosis in solid tumor cells by simultaneously targeting death receptors, c-FLIP and IAPs","volume":"49","author":"Huang","year":"2016","journal-title":"Int J Oncol"},{"key":"key20221222114858_b60-ijmm-51-1-05206","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1172\/JCI6926","article-title":"Safety and antitumor activity of recombinant soluble Apo2 ligand","volume":"104","author":"Ashkenazi","year":"1999","journal-title":"J Clin Invest"},{"key":"key20221222114858_b61-ijmm-51-1-05206","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1038\/gt.2017.86","article-title":"Efficacy of combining ING4 and TRAIL genes in cancer-targeting gene virotherapy strategy: First evidence in preclinical hepatocellular carcinoma","volume":"25","author":"Galal El-Shemi","year":"2018","journal-title":"Gene Ther"},{"key":"key20221222114858_b62-ijmm-51-1-05206","doi-asserted-by":"publisher","first-page":"2839","DOI":"10.1200\/JCO.2009.25.1991","article-title":"Phase I dose-escalation study of recombinant human Apo2L\/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer","volume":"28","author":"Herbst","year":"2010","journal-title":"J Clin Oncol"},{"key":"key20221222114858_b63-ijmm-51-1-05206","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/1074-7613(95)90057-8","article-title":"Identification and characterization of a new member of the TNF family that induces apoptosis","volume":"3","author":"Wiley","year":"1995","journal-title":"Immunity"},{"key":"key20221222114858_b64-ijmm-51-1-05206","doi-asserted-by":"publisher","first-page":"12687","DOI":"10.1074\/jbc.271.22.12687","article-title":"Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family","volume":"271","author":"Pitti","year":"1996","journal-title":"J Biol Chem"},{"key":"key20221222114858_b65-ijmm-51-1-05206","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1002\/hep.29513","article-title":"A multifunctional nanocarrier for efficient TRAIL-based gene therapy against hepatocellular carcinoma with desmoplasia in mice","volume":"67","author":"Liu","year":"2018","journal-title":"Hepatology"},{"key":"key20221222114858_b66-ijmm-51-1-05206","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/sj.gt.3302658","article-title":"Cancer gene therapy using a novel secretable trimeric TRAIL","volume":"13","author":"Kim","year":"2006","journal-title":"Gene Ther"},{"key":"key20221222114858_b67-ijmm-51-1-05206","doi-asserted-by":"publisher","first-page":"3718","DOI":"10.1158\/0008-5472.CAN-09-1865","article-title":"Adipose-derived mesenchymal stem cells as stable source of tumor necrosis factor-related apoptosis-inducing ligand delivery for cancer therapy","volume":"70","author":"Grisendi","year":"2010","journal-title":"Cancer Res"},{"key":"key20221222114858_b68-ijmm-51-1-05206","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s12935-020-01724-8","article-title":"TRAIL promotes hepatocellular carcinoma apoptosis and inhibits proliferation and migration via interacting with IER3","volume":"21","author":"Liu","year":"2021","journal-title":"Cancer Cell Int"},{"key":"key20221222114858_b69-ijmm-51-1-05206","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1038\/cdd.2014.81","article-title":"Getting TRAIL back on track for cancer therapy","volume":"21","author":"Lemke","year":"2014","journal-title":"Cell Death Differ"},{"key":"key20221222114858_b70-ijmm-51-1-05206","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.cytogfr.2013.12.009","article-title":"Death receptor agonist therapies for cancer, which is the right TRAIL?","volume":"25","author":"Holland","year":"2014","journal-title":"Cytokine Growth Factor Rev"},{"key":"key20221222114858_b71-ijmm-51-1-05206","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1038\/sj.gt.3301797","article-title":"Mechanisms involved in development of resistance to adenovirus-mediated proapoptotic gene therapy in DLD1 human colon cancer cell line","volume":"9","author":"Zhang","year":"2002","journal-title":"Gene Ther"},{"key":"key20221222114858_b72-ijmm-51-1-05206","doi-asserted-by":"publisher","first-page":"5477","DOI":"10.1038\/sj.onc.1203936","article-title":"Bcl-XL protects pancreatic adenocarcinoma cells against CD95- and TRAIL-receptor-mediated apoptosis","volume":"19","author":"Hinz","year":"2000","journal-title":"Oncogene"},{"key":"key20221222114858_b73-ijmm-51-1-05206","first-page":"1314","article-title":"Resistance to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in neuroblastoma cells correlates with a loss of caspase-8 expression","volume":"61","author":"Eggert","year":"2001","journal-title":"Cancer Res"},{"key":"key20221222114858_b74-ijmm-51-1-05206","doi-asserted-by":"publisher","first-page":"5145","DOI":"10.1038\/sj.onc.1209516","article-title":"Combined treatment of colorectal tumours with agonistic TRAIL receptor antibodies HGS-ETR1 and HGS-ETR2 and radiotherapy: Enhanced effects in vitro and dose-dependent growth delay in vivo","volume":"25","author":"Marini","year":"2006","journal-title":"Oncogene"},{"key":"key20221222114858_b75-ijmm-51-1-05206","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1038\/sj.bjc.6602487","article-title":"HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo","volume":"92","author":"Pukac","year":"2005","journal-title":"Br J Cancer"},{"key":"key20221222114858_b76-ijmm-51-1-05206","first-page":"31","article-title":"Preclinical studies to predict the disposition of Apo2L\/tumor necrosis factor-related apoptosis-inducing ligand in humans: characterization of in vivo efcacy, pharmacokinetics, and safety","volume":"299","author":"Kelley","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"key":"key20221222114858_b77-ijmm-51-1-05206","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1021\/bi992242l","article-title":"A unique zinc-binding site revealed by a high-resolution X-ray structure of homotrimeric Apo2L\/TRAIL","volume":"39","author":"Hymowitz","year":"2000","journal-title":"Biochemistry"},{"key":"key20221222114858_b78-ijmm-51-1-05206","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1517\/14728222.11.10.1299","article-title":"TRAIL in cancer therapy: Present and future challenges","volume":"11","author":"M\u00e9rino","year":"2007","journal-title":"Expert Opin Ther Targets"},{"key":"key20221222114858_b79-ijmm-51-1-05206","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1038\/86397","article-title":"Differential hepatocyte toxicity of recombinant Apo2L\/TRAIL versions","volume":"7","author":"Lawrence","year":"2001","journal-title":"Nat Med"},{"key":"key20221222114858_b80-ijmm-51-1-05206","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1038\/sj.bjc.6604459","article-title":"In vitro sensitivity testing of minimally passaged and uncultured gliomas with TRAIL and\/or chemotherapy drugs","volume":"99","author":"Ashley","year":"2008","journal-title":"Br J Cancer"},{"key":"key20221222114858_b81-ijmm-51-1-05206","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1016\/j.biomaterials.2011.10.050","article-title":"Doxorubicin-loaded human serum albumin nanoparticles surface-modified with TNF-related apoptosis-inducing ligand and transferrin for targeting multiple tumor types","volume":"33","author":"Bae","year":"2012","journal-title":"Biomaterials"},{"key":"key20221222114858_b82-ijmm-51-1-05206","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1073\/pnas.1316312111","article-title":"TRAIL-coated leukocytes that kill cancer cells in the circulation","volume":"111","author":"Mitchell","year":"2014","journal-title":"Proc Natl Acad Sci USA"},{"key":"key20221222114858_b83-ijmm-51-1-05206","doi-asserted-by":"publisher","first-page":"444","DOI":"10.3390\/cancers11040444","article-title":"Importance of TRAIL molecular anatomy in receptor oligomerization and signaling Implications for cancer therapy","volume":"11","author":"Naval","year":"2019","journal-title":"Cancers (Basel)"},{"key":"key20221222114858_b84-ijmm-51-1-05206","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1084\/jem.189.8.1343","article-title":"Monocyte-mediated tumoricidal activity via the tumor necrosis factor-related cytokine, TRAIL","volume":"189","author":"Griffith","year":"1999","journal-title":"J Exp Med"},{"key":"key20221222114858_b85-ijmm-51-1-05206","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.4049\/jimmunol.162.5.2639","article-title":"Involvement of TNF-related apoptosis-inducing ligand in human CD4+ T cell-mediated cytotoxicity","volume":"162","author":"Kayagaki","year":"1999","journal-title":"J Immunol"},{"key":"key20221222114858_b86-ijmm-51-1-05206","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1002\/(SICI)1521-4141(200004)30:4<1078::AID-IMMU1078>3.0.CO;2-Q","article-title":"CD59 cross-linking induces secretion of APO2 ligand in overactivated human T cells","volume":"30","author":"Monle\u00f3n","year":"2000","journal-title":"Eur J Immunol"},{"key":"key20221222114858_b87-ijmm-51-1-05206","doi-asserted-by":"publisher","first-page":"6736","DOI":"10.4049\/jimmunol.167.12.6736","article-title":"Differential secretion of Fas ligand- or APO2 ligand\/TNF-related apoptosis-inducing ligand-carrying microvesicles during activation-induced death of human T cells","volume":"167","author":"Monle\u00f3n","year":"2001","journal-title":"J Immunol"},{"key":"key20221222114858_b88-ijmm-51-1-05206","doi-asserted-by":"publisher","first-page":"4101","DOI":"10.1038\/sj.onc.1204558","article-title":"Differential activation of TRAIL-R1 and -2 by soluble and membrane TRAIL allows selective surface antigen-directed activation of TRAIL-R2 by a soluble TRAIL derivative","volume":"20","author":"Wajant","year":"2001","journal-title":"Oncogene"},{"key":"key20221222114858_b89-ijmm-51-1-05206","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1021\/mp300258c","article-title":"Liposomes decorated with Apo2L\/TRAIL overcome chemoresistance of human hematologic tumor cells","volume":"10","author":"De Miguel","year":"2013","journal-title":"Mol Pharm"},{"key":"key20221222114858_b90-ijmm-51-1-05206","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/j.leukres.2015.03.019","article-title":"Liposome-bound TRAIL induces superior DR5 clustering and enhanced DISC recruitment in histiocytic lymphoma U937 cells","volume":"39","author":"De Miguel","year":"2015","journal-title":"Leuk Res"},{"key":"key20221222114858_b91-ijmm-51-1-05206","doi-asserted-by":"publisher","first-page":"185101","DOI":"10.1088\/0957-4484\/27\/18\/185101","article-title":"TRAIL-coated lipid-nanoparticles overcome resistance to soluble recombinant TRAIL in non-small cell lung cancer cells","volume":"27","author":"De Miguel","year":"2016","journal-title":"Nanotechnology"},{"key":"key20221222114858_b92-ijmm-51-1-05206","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.canlet.2016.10.005","article-title":"High-order TRAIL oligomer formation in TRAIL-coated lipid nanoparticles enhances DR5 cross-linking and increases antitumour effect against colon cancer","volume":"383","author":"De Miguel","year":"2016","journal-title":"Cancer Lett"},{"key":"key20221222114858_b93-ijmm-51-1-05206","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.jconrel.2010.10.037","article-title":"PEGylated TNF-related apoptosis-inducing ligand (TRAIL)-loaded sustained release PLGA microspheres for enhanced stability and antitumor activity","volume":"150","author":"Kim","year":"2011","journal-title":"J Control Release"},{"key":"key20221222114858_b94-ijmm-51-1-05206","doi-asserted-by":"publisher","first-page":"8628","DOI":"10.1038\/sj.onc.1207232","article-title":"TRAIL and apoptosis induction by TNF-family death receptors","volume":"22","author":"Wang","year":"2003","journal-title":"Oncogene"},{"key":"key20221222114858_b95-ijmm-51-1-05206","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.canlet.2020.05.004","article-title":"Exosomes as drug delivery vehicle and contributor of resistance to anticancer drugs","volume":"486","author":"Chinnappan","year":"2020","journal-title":"Cancer Lett"},{"key":"key20221222114858_b96-ijmm-51-1-05206","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.jconrel.2017.10.020","article-title":"Exosome is a mechanism of inter-cellular drug transfer: Application of quantitative pharmacology","volume":"268","author":"Wang","year":"2017","journal-title":"J Control Release"},{"key":"key20221222114858_b97-ijmm-51-1-05206","doi-asserted-by":"publisher","first-page":"R125","DOI":"10.1093\/hmg\/dds317","article-title":"Exosomes and microvesicles: Extracellular vesicles for genetic information transfer and gene therapy","volume":"21","author":"Lee","year":"2012","journal-title":"Hum Mol Genet"},{"key":"key20221222114858_b98-ijmm-51-1-05206","doi-asserted-by":"publisher","first-page":"e84256","DOI":"10.1371\/journal.pone.0084256","article-title":"Exosomes derived from mesenchymal stem cells suppress angiogenesis by down-regulating VEGF expression in breast cancer cells","volume":"8","author":"Lee","year":"2013","journal-title":"PLoS One"},{"key":"key20221222114858_b99-ijmm-51-1-05206","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/j.tibtech.2017.03.004","article-title":"Exosomes in cancer nanomedicine and immunotherapy: Prospects and challenges","volume":"35","author":"Syn","year":"2017","journal-title":"Trends Biotechnol"},{"key":"key20221222114858_b100-ijmm-51-1-05206","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.apsb.2016.02.001","article-title":"Exosomes as therapeutic drug carriers and delivery vehicles across biological membranes: Current perspectives and future challenges","volume":"6","author":"Ha","year":"2016","journal-title":"Acta Pharm Sin B"},{"key":"key20221222114858_b101-ijmm-51-1-05206","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/j.biotechadv.2017.12.010","article-title":"Exosome biogenesis, bioactivities and functions as new delivery systems of natural compounds","volume":"36","author":"Farooqi","year":"2018","journal-title":"Biotechnol Adv"},{"key":"key20221222114858_b102-ijmm-51-1-05206","doi-asserted-by":"publisher","first-page":"18","DOI":"10.3389\/fcell.2018.00018","article-title":"Exosome-based cell-cell communication in the tumor microenvironment","volume":"6","author":"Maia","year":"2018","journal-title":"Front Cell Dev Biol"},{"key":"key20221222114858_b103-ijmm-51-1-05206","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/j.addr.2012.07.001","article-title":"Mesenchymal stem cell: An efficient mass producer of exosomes for drug delivery","volume":"65","author":"Yeo","year":"2013","journal-title":"Adv Drug Deliv Rev"},{"key":"key20221222114858_b104-ijmm-51-1-05206","doi-asserted-by":"publisher","first-page":"e346","DOI":"10.1038\/emm.2017.63","article-title":"Mesenchymal stem cell-derived exosomes as a new therapeutic strategy for liver diseases","volume":"49","author":"Lou","year":"2017","journal-title":"Exp Mol Med"},{"key":"key20221222114858_b105-ijmm-51-1-05206","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1186\/s13287-018-0939-5","article-title":"Exosomes derived from human adipose tissue-derived mesenchymal stem cells alleviate atopic dermatitis","volume":"9","author":"Cho","year":"2018","journal-title":"Stem Cell Res Ther"},{"key":"key20221222114858_b106-ijmm-51-1-05206","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.1038\/nprot.2012.131","article-title":"Exosome-mediated delivery of siRNA in vitro and in vivo","volume":"7","author":"El-Andaloussi","year":"2012","journal-title":"Nat Protoc"},{"key":"key20221222114858_b107-ijmm-51-1-05206","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.colsurfb.2011.05.013","article-title":"Characterisation of exosomes derived from human cells by nanoparticle tracking analysis and scanning electron microscopy","volume":"87","author":"Sokolova","year":"2011","journal-title":"Colloids Surf B Biointerfaces"},{"key":"key20221222114858_b108-ijmm-51-1-05206","doi-asserted-by":"publisher","first-page":"3354","DOI":"10.1002\/pmic.201300282","article-title":"Comparative proteomics evaluation of plasma exosome isolation techniques and assessment of the stability of exosomes in normal human blood plasma","volume":"13","author":"Kalra","year":"2013","journal-title":"Proteomics"},{"key":"key20221222114858_b109-ijmm-51-1-05206","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1038\/mt.2015.44","article-title":"Mesenchymal stem cell-derived extracellular vesicles: Toward cell-free therapeutic applications","volume":"23","author":"Rani","year":"2015","journal-title":"Mol Ther"},{"key":"key20221222114858_b110-ijmm-51-1-05206","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.jcyt.2015.11.018","article-title":"Safety evaluation of exosomes derived from human umbilical cord mesenchymal stromal cell","volume":"18","author":"Sun","year":"2016","journal-title":"Cytotherapy"},{"key":"key20221222114858_b111-ijmm-51-1-05206","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/nbt.1807","article-title":"Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes","volume":"29","author":"Alvarez-Erviti","year":"2011","journal-title":"Nat Biotechnol"},{"key":"key20221222114858_b112-ijmm-51-1-05206","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.addr.2012.08.008","article-title":"Exosomes for targeted siRNA delivery across biological barriers","volume":"65","author":"El Andaloussi","year":"2013","journal-title":"Adv Drug Deliv Rev"},{"key":"key20221222114858_b113-ijmm-51-1-05206","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/1479-5876-3-10","article-title":"Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: Results of thefirst phase I clinical trial","volume":"3","author":"Escudier","year":"2005","journal-title":"J Transl Med"},{"key":"key20221222114858_b114-ijmm-51-1-05206","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/1479-5876-3-9","article-title":"A phase I study of dexosome immunotherapy in patients with advanced non-small cell lung cancer","volume":"3","author":"Morse","year":"2005","journal-title":"J Transl Med"},{"key":"key20221222114858_b115-ijmm-51-1-05206","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1038\/mt.2008.1","article-title":"Phase I clinical trial of autologous ascites-derived exosomes combined with GM-CSF for colorectal cancer","volume":"16","author":"Dai","year":"2008","journal-title":"Mol Ther"},{"key":"key20221222114858_b116-ijmm-51-1-05206","doi-asserted-by":"publisher","first-page":"2296","DOI":"10.1002\/jcp.27214","article-title":"Exosomes and microRNAs: New potential therapeutic candidates in Alzheimer disease therapy","volume":"234","author":"Iranifar","year":"2019","journal-title":"J Cell Physiol"},{"key":"key20221222114858_b117-ijmm-51-1-05206","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.jconrel.2018.08.035","article-title":"Dopamine-loaded blood exosomes targeted to brain for better treatment of Parkinson's disease","volume":"287","author":"Qu","year":"2018","journal-title":"J Control Release"},{"key":"key20221222114858_b118-ijmm-51-1-05206","doi-asserted-by":"publisher","first-page":"7481","DOI":"10.1039\/C9NR01255A","article-title":"Curcumin-primed exosomes potently ameliorate cognitive function in AD mice by inhibiting hyperphosphorylation of the Tau protein through the AKT\/GSK-3\u03b2 pathway","volume":"11","author":"Wang","year":"2019","journal-title":"Nanoscale"},{"key":"key20221222114858_b119-ijmm-51-1-05206","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.nano.2017.09.011","article-title":"Engineering macro-phage-derived exosomes for targeted paclitaxel delivery to pulmonary metastases: In vitro and in vivo evaluations","volume":"14","author":"Kim","year":"2018","journal-title":"Nanomedicine"},{"key":"key20221222114858_b120-ijmm-51-1-05206","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1007\/s10555-013-9441-9","article-title":"Exosomes in cancer development, metastasis, and drug resistance: A comprehensive review","volume":"32","author":"Azmi","year":"2013","journal-title":"Cancer Metastasis Rev"},{"key":"key20221222114858_b121-ijmm-51-1-05206","doi-asserted-by":"publisher","first-page":"e99263","DOI":"10.1172\/jci.insight.99263","article-title":"Generation and testing of clinical-grade exosomes for pancreatic cancer","volume":"3","author":"Mendt","year":"2018","journal-title":"JCI Insight"},{"key":"key20221222114858_b122-ijmm-51-1-05206","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s13024-016-0143-y","article-title":"The release and trans-synaptic transmission of Tau via exosomes","volume":"12","author":"Wang","year":"2017","journal-title":"Mol Neurodegener"},{"key":"key20221222114858_b123-ijmm-51-1-05206","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.ijpharm.2017.02.038","article-title":"Exosomes as novel bio-carriers for gene and drug delivery","volume":"521","author":"Jiang","year":"2017","journal-title":"Int J Pharm"},{"key":"key20221222114858_b124-ijmm-51-1-05206","doi-asserted-by":"publisher","first-page":"2431","DOI":"10.2217\/nnm-2016-0154","article-title":"Exosomes increase the therapeutic index of doxorubicin in breast and ovarian cancer mouse models","volume":"11","author":"Hadla","year":"2016","journal-title":"Nanomedicine (Lond)"},{"key":"key20221222114858_b125-ijmm-51-1-05206","doi-asserted-by":"publisher","first-page":"2954","DOI":"10.1016\/j.bbamem.2014.07.026","article-title":"Examination of the specificity of tumor cell derived exosomes with tumor cells in vitro","volume":"1838","author":"Smyth","year":"2014","journal-title":"Biochim Biophys Acta"},{"key":"key20221222114858_b126-ijmm-51-1-05206","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/j.nano.2015.10.012","article-title":"Development of exosome-encapsulated paclitaxel to overcome MDR in cancer cells","volume":"12","author":"Kim","year":"2016","journal-title":"Nanomedicine"},{"key":"key20221222114858_b127-ijmm-51-1-05206","doi-asserted-by":"publisher","first-page":"16014","DOI":"10.1038\/natrevmats.2016.14","article-title":"Analysis of nanoparticle delivery to tumours","volume":"1","author":"Wilhelm","year":"2016","journal-title":"Nat Rev Mater"},{"key":"key20221222114858_b128-ijmm-51-1-05206","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/j.jhep.2019.09.010","article-title":"Molecular therapies for HCC: Looking outside the box","volume":"72","author":"Faivre","year":"2020","journal-title":"J Hepatol"},{"key":"key20221222114858_b129-ijmm-51-1-05206","doi-asserted-by":"publisher","first-page":"69","DOI":"10.3389\/fonc.2015.00069","article-title":"Trailing TRAIL resistance: Novel targets for TRAIL sensitization in cancer cells","volume":"5","author":"Trivedi","year":"2015","journal-title":"Front Oncol"},{"key":"key20221222114858_b130-ijmm-51-1-05206","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1016\/j.ymthe.2017.03.030","article-title":"Engineered exosomes as vehicles for biologically active proteins","volume":"25","author":"Sterzenbach","year":"2017","journal-title":"Mol Ther"},{"key":"key20221222114858_b131-ijmm-51-1-05206","doi-asserted-by":"publisher","first-page":"3499","DOI":"10.1158\/1078-0432.CCR-15-2170","article-title":"TNF-related apoptosis-inducing ligand (TRAIL)-armed exosomes deliver proapoptotic signals to tumor site","volume":"22","author":"Rivoltini","year":"2016","journal-title":"Clin Cancer Res"},{"key":"key20221222114858_b132-ijmm-51-1-05206","doi-asserted-by":"publisher","first-page":"1265291","DOI":"10.1080\/20013078.2017.1265291","article-title":"TRAIL delivery by MSC-derived extracellular vesicles is an effective anticancer therapy","volume":"6","author":"Yuan","year":"2017","journal-title":"J Extracell Vesicles"},{"key":"key20221222114858_b133-ijmm-51-1-05206","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.ijpharm.2018.07.067","article-title":"Exosomes derived from TRAIL-engineered mesenchymal stem cells with effective anti-tumor activity in a mouse melanoma model","volume":"549","author":"Shamili","year":"2018","journal-title":"Int J Pharm"},{"key":"key20221222114858_b134-ijmm-51-1-05206","doi-asserted-by":"publisher","first-page":"101","DOI":"10.3892\/ijo.2012.1676","article-title":"Sorafenib and TRAIL have synergistic effect on hepatocellular carcinoma","volume":"42","author":"Nojiri","year":"2013","journal-title":"Int J Oncol"},{"key":"key20221222114858_b135-ijmm-51-1-05206","doi-asserted-by":"publisher","first-page":"5189","DOI":"10.1158\/1078-0432.CCR-09-3389","article-title":"Sorafenib overcomes TRAIL resistance of hepatocellular carcinoma cells through the inhibition of STAT3","volume":"16","author":"Chen","year":"2010","journal-title":"Clin Cancer Res"},{"key":"key20221222114858_b136-ijmm-51-1-05206","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.3390\/cells9102271","article-title":"Therapeutic miRNA-enriched extracellular vesicles: Current approaches and future prospects","volume":"9","author":"Munir","year":"2020","journal-title":"Cells"},{"key":"key20221222114858_b137-ijmm-51-1-05206","doi-asserted-by":"publisher","first-page":"17581","DOI":"10.1038\/s41598-018-35968-2","article-title":"Extracellular vesicles produced in B cells deliver tumor suppressor miR-335 to breast cancer cells disrupting oncogenic programming in vitro and in vivo","volume":"8","author":"Almanza","year":"2018","journal-title":"Sci Rep"},{"key":"key20221222114858_b138-ijmm-51-1-05206","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1002\/hep.28735","article-title":"Extracellular vesicles carry microRNA-195 to intrahepatic cholangiocarcinoma and improve survival in a rat model","volume":"65","author":"Li","year":"2017","journal-title":"Hepatology"},{"key":"key20221222114858_b139-ijmm-51-1-05206","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1002\/hep.29586","article-title":"Exosome miR-335 as a novel therapeutic strategy in hepatocellular carcinoma","volume":"67","author":"Wang","year":"2018","journal-title":"Hepatology"},{"key":"key20221222114858_b140-ijmm-51-1-05206","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.3389\/fphys.2018.01169","article-title":"Exosomes from human cardiac progenitor cells for therapeutic applications: Development of a GMP-grade manufacturing method","volume":"9","author":"Andriolo","year":"2018","journal-title":"Front Physiol"},{"key":"key20221222114858_b141-ijmm-51-1-05206","doi-asserted-by":"publisher","first-page":"26","DOI":"10.3892\/mmr.2021.12542","article-title":"Possibility of exosome-based coronavirus disease 2019 vaccine (review)","volume":"25","author":"Yoo","year":"2022","journal-title":"Mol Med Rep"},{"key":"key20221222114858_b142-ijmm-51-1-05206","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1007\/s13346-016-0319-6","article-title":"Computational pharmacokinetic rationale for intra-arterial delivery to the brain","volume":"6","author":"Cooke","year":"2016","journal-title":"Drug Deliv Transl Res"},{"key":"key20221222114858_b143-ijmm-51-1-05206","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1093\/annonc\/mdw004","article-title":"A randomized, double-blind, placebo-controlled phase II study to assess the efficacy and safety of mapatumumab with sorafenib in patients with advanced hepatocellular carcinoma","volume":"27","author":"Ciuleanu","year":"2016","journal-title":"Ann Oncol"},{"key":"key20221222114858_b144-ijmm-51-1-05206","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.cllc.2013.12.005","article-title":"Phase II trial of mapatumumab, a fully human agonist monoclonal anti-body to tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1), in combination with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer","volume":"15","author":"von Pawel","year":"2014","journal-title":"Clin Lung Cancer"},{"key":"key20221222114858_b145-ijmm-51-1-05206","doi-asserted-by":"publisher","first-page":"TPS9116","DOI":"10.1200\/JCO.2019.37.15_suppl.TPS9116","article-title":"TACTICAL: A phase I\/II trial to assess the safety and efficacy of MSCTRAIL in the treatment of metastatic lung adenocarcinoma","volume":"37","author":"Davies","year":"2019","journal-title":"J Clin Oncol"},{"key":"key20221222114858_b146-ijmm-51-1-05206","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1007\/s10637-016-0420-1","article-title":"First-in-human study of the antibody DR5 agonist DS-8273a in patients with advanced solid tumors","volume":"35","author":"Forero","year":"2017","journal-title":"Invest New Drugs"},{"key":"key20221222114858_b147-ijmm-51-1-05206","doi-asserted-by":"publisher","first-page":"2655","DOI":"10.1111\/j.1582-4934.2009.00851.x","article-title":"Membrane-bound HSP70-engineered myeloma cell-derived exosomes stimulate more efficient CD8(+) CTL- and NK-mediated antitumour immunity than exosomes released from heat-shocked tumour cells expressing cytoplasmic HSP70","volume":"14","author":"Xie","year":"2010","journal-title":"J Cell Mol Med"},{"key":"key20221222114858_b148-ijmm-51-1-05206","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.3390\/cancers12051157","article-title":"Extracellular vesicle delivery of TRAIL eradicates resistant tumor growth in combination with CDK inhibition by dinaciclib","volume":"12","author":"Ke","year":"2020","journal-title":"Cancers (Basel)"},{"key":"key20221222114858_b149-ijmm-51-1-05206","doi-asserted-by":"publisher","first-page":"3550","DOI":"10.3390\/cancers14143550","article-title":"Pulmonary delivery of extracellular vesicle-encapsulated dinaciclib as an effective lung cancer therapy","volume":"14","author":"Yuan","year":"2022","journal-title":"Cancers (Basel)"},{"key":"key20221222114858_b150-ijmm-51-1-05206","doi-asserted-by":"publisher","first-page":"42411","DOI":"10.1021\/acsami.1c10325","article-title":"Engineering exosomes endowed with targeted delivery of triptolide for malignant melanoma therapy","volume":"13","author":"Jiang","year":"2021","journal-title":"ACS Appl Mater Interfaces"}],"container-title":["International Journal of Molecular Medicine"],"original-title":[],"deposited":{"date-parts":[[2023,3,13]],"date-time":"2023-03-13T00:29:08Z","timestamp":1678667348000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/ijmm.2022.5206"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,18]]},"references-count":150,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,11,18]]}},"URL":"https:\/\/doi.org\/10.3892\/ijmm.2022.5206","relation":{},"ISSN":["1107-3756","1791-244X"],"issn-type":[{"value":"1107-3756","type":"print"},{"value":"1791-244X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,18]]},"article-number":"3"}}